Cargando…

Ibandronate to treat skeletal-related events and bone pain in metastatic bone disease or multiple myeloma: a meta-analysis of randomised clinical trials

OBJECTIVE: Randomised controlled trials (RCTs) have given contradictory results about the efficacy and safety of ibandronate in treating metastatic bone disease (MBD) or multiple myeloma. This review meta-analysed the literature to gain a more comprehensive picture. DESIGN: Systematic review and met...

Descripción completa

Detalles Bibliográficos
Autores principales:	Geng, Chun-Jing, Liang, Qian, Zhong, Jian-Hong, Zhu, Min, Meng, Fan-Ying, Wu, Ning, Liang, Rui, Yuan, Bin-Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2015
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4458633/ https://www.ncbi.nlm.nih.gov/pubmed/26038356 http://dx.doi.org/10.1136/bmjopen-2014-007258

Ejemplares similares

Ibandronate: The loading dose concept in the treatment of metastatic bone pain
por: Maier, Gerrit Steffen, et al.
Publicado: (2015)

Use of ibandronate in the prevention of skeletal events in metastatic breast cancer
por: Devitt, Bianca, et al.
Publicado: (2008)

Efficacy of Ibandronate Loading Dose on Rapid Pain Relief in Patients With Non-Small Cell Lung Cancer and Cancer Induced Bone Pain: The NVALT-9 Trial
por: Brouns, Anita J. W. M., et al.
Publicado: (2020)

Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies
por: Body, J J, et al.
Publicado: (2004)

Effect of lumbar spinal stenosis on bone mineral density in osteoporosis patients treated with ibandronate
por: Park, Hyung-Youl, et al.
Publicado: (2021)

Comparative Effects of Ibandronate and Paclitaxel on Immunocompetent Bone Metastasis Model
por: Chung, Yoon-Sok, et al.
Publicado: (2015)

The influence of ibandronate treatment on bone density and biochemical bone markers in patients with osteogenesis imperfecta
por: Ipach, Ingmar, et al.
Publicado: (2012)

Effects of zoledronic acid and ibandronate in the treatment of cancer pain in rats with lung cancer combined with bone metastases
por: Wang, Gengshen, et al.
Publicado: (2018)

Metabolic features of myeloma cells in the context of bone microenvironment: Implication for the pathophysiology and clinic of myeloma bone disease
por: Raimondi, Vincenzo, et al.
Publicado: (2022)

Skeletal-Related Events After Surgery With or Without Radiotherapy for Bone Metastases to Weight-Bearing Bones
por: Lanier, Claire M, et al.
Publicado: (2022)

Ibandronate Reduces the Surface Bone Resorption of Mandibular Bone Grafts: A Randomized Trial With Internal Controls
por: Abtahi, Jahan, et al.
Publicado: (2021)

Validation of symptom clusters in patients with metastatic bone pain
por: Hadi, S., et al.
Publicado: (2008)

Game of Bones: How Myeloma Manipulates Its Microenvironment
por: Moser-Katz, Tyler, et al.
Publicado: (2021)

Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long-term glucocorticoid
por: Li, Edmund K, et al.
Publicado: (2010)

Effect of ibandronate on bending strength and toughness of rodent cortical bone: Possible implications for fracture prevention
por: Savaridas, T., et al.
Publicado: (2015)

Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women
por: Sambrook, Philip
Publicado: (2007)

The role of the bone microenvironment in regulating myeloma residual disease and treatment
por: Dadzie, Terry G., et al.
Publicado: (2022)

Promotion of Bone Lesions Through the Myeloma Integrin α6-Mediated Osteolytic Signaling
por: Liu, Huan, et al.
Publicado: (2021)

Intermittent Ibandronate Maintains Bone Mass, Bone Structure, and Biomechanical Strength of Trabecular and Cortical Bone After Discontinuation of Parathyroid Hormone Treatment in Ovariectomized Rats
por: Takeda, Satoshi, et al.
Publicado: (2017)

Plasma Circulating Tumor Epstein–Barr Virus for the Surveillance of Cancer Progression in Bone-Only Metastatic Nasopharyngeal Carcinoma
por: Liu, Guo-Ying, et al.
Publicado: (2022)

RRBP1 depletion of bone metastatic cancer cells contributes to enhanced expression of the osteoblastic phenotype
por: Chen, Rui, et al.
Publicado: (2022)

Zoledronic acid is more efficient than ibandronic acid in the treatment of symptomatic bone marrow lesions of the knee
por: Müller, Fabio, et al.
Publicado: (2019)

Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis
por: Uehara, Masashi, et al.
Publicado: (2021)

Exosomes in the Pathogenesis and Treatment of Multiple Myeloma in the Context of the Bone Marrow Microenvironment
por: Chen, Tianzeng, et al.
Publicado: (2020)

Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche
por: Solimando, Antonio Giovanni, et al.
Publicado: (2022)

Editorial: The role of the bone marrow microenvironment in multiple myeloma evolution and therapy
por: Schinke, Carolina, et al.
Publicado: (2023)

Review of Bone Modifying Agents in Metastatic Breast Cancer
por: Raghu Subramanian, Charumathi, et al.
Publicado: (2021)

Management of pain in patients with bone metastases
por: Jing, Doudou, et al.
Publicado: (2023)

Bone resorption predicts for skeletal complications in metastatic bone disease
por: Brown, J E, et al.
Publicado: (2003)

Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain
por: Gdowski, Andrew S, et al.
Publicado: (2017)

Bone Scan Index predicts skeletal-related events in patients with metastatic breast cancer
por: Idota, Ai, et al.
Publicado: (2016)

The importance of retaining physical functions to prevent skeletal‐related events in multiple myeloma patients with bone disease
por: Miki, Hirokazu, et al.
Publicado: (2022)

Complete remission of metastatic renal cell carcinoma to the bone with sunitinib
por: Yoshimura, Akihiro, et al.
Publicado: (2020)

Comparison of Monthly Ibandronate Versus Weekly Risedronate in Preference, Convenience, and Bone Turnover Markers in Korean Postmenopausal Osteoporotic Women
por: Chung, Yoon-Sok, et al.
Publicado: (2009)

Prevention of anastrozole induced bone loss with monthly oral ibandronate: Final 5 year results from the ARIBON trial
por: Lester, J.E., et al.
Publicado: (2012)

Preparation, Characterization, and Preliminary Imaging Study of [(188)Re]Re-Ibandronate as a Novel Theranostic Radiopharmaceutical for Bone Metastasis
por: Xu, Tingting, et al.
Publicado: (2022)

Effects of ibandronate-hydroxyapatite on resorptive activity of osteoclasts
por: Zhang, Xiaohui, et al.
Publicado: (2011)

Treatment of Polyostotic Fibrous Dysplasia With Intravenous Ibandronate
por: Kazi, Fatima M, et al.
Publicado: (2021)

Synchronous Bone Metastasis From Multiple Myeloma and Prostate Adenocarcinoma as Initial Presentation of Coexistent Malignancies
por: Adrianzen Herrera, Diego Andres, et al.
Publicado: (2018)

Can Targeting Hypoxia-Mediated Acidification of the Bone Marrow Microenvironment Kill Myeloma Tumor Cells?
por: Gastelum, Gilberto, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cncsuplndqi69n7hqto8k37hqd